{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:12:02Z","timestamp":1778803922530,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02718-0","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:02:20Z","timestamp":1778803340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Shao-Hua","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Jun","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-He","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9423-1258","authenticated-orcid":false,"given":"Long-Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Ce","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Ping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2718_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA. Cancer J. Clin."},{"key":"2718_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"2718_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","volume":"6","author":"A Vogel","year":"2021","unstructured":"Vogel, A. et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol. Hepatol. 6, 649\u2013658 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"2718_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391, 1163\u20131173 (2018).","journal-title":"Lancet"},{"key":"2718_CR5","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa, G. K. et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 1, 0\u201312 (2022).","journal-title":"NEJM Evid."},{"key":"2718_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894\u20131905 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2718_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2024.07.017","volume":"82","author":"G Lau","year":"2025","unstructured":"Lau, G. et al. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. J. Hepatol. 82, 258\u2013267 (2025).","journal-title":"J. Hepatol."},{"key":"2718_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-025-02498-z","volume":"11","author":"X Zhang","year":"2026","unstructured":"Zhang, X. et al. Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study. Signal Transduct. Targeted Ther. 11, 37\u201351 (2026).","journal-title":"Signal Transduct. Targeted Ther."},{"key":"2718_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"Q-J Li","year":"2022","unstructured":"Li, Q.-J. et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J. Clin. Oncol. 40, 150\u2013160 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2718_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.21037\/hbsn.2020.03.14","volume":"10","author":"S Li","year":"2021","unstructured":"Li, S. et al. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice. Hepatobiliary Surg. Nutr. 10, 631\u2013645 (2021).","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"2718_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2718_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1097\/HEP.0000000000000572","volume":"81","author":"V Zanuso","year":"2025","unstructured":"Zanuso, V., Rimassa, L. & Braconi, C. The rapidly evolving landscape of HCC: selecting the optimal systemic therapy. Hepatology 81, 1365\u20131386 (2025).","journal-title":"Hepatology"},{"key":"2718_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-024-01647-1","volume":"17","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Dai, S., Cheng, C. & Chen, L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J. Hematol. Oncol. 17, 130\u2013170 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2718_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2019.09.023","volume":"72","author":"DH Palmer","year":"2020","unstructured":"Palmer, D. H., Malagari, K. & Kulik, L. M. Role of locoregional therapies in the wake of systemic therapy. J. Hepatol. 72, 277\u2013287 (2020).","journal-title":"J. Hepatol."},{"key":"2718_CR15","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"S-H Li","year":"2023","unstructured":"Li, S.-H. et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase III, randomized study. J. Clin. Oncol. 41, 1898\u20131908 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2718_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N. Engl. J. Med. 377, 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2718_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro, B. et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 405, 216\u2013232 (2025).","journal-title":"Lancet"},{"key":"2718_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo, M. et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 405, 203\u2013215 (2025).","journal-title":"Lancet"},{"key":"2718_CR19","first-page":"0","volume":"43","author":"H Zhu","year":"2025","unstructured":"Zhu, H. et al. Transarterial chemoembolization (TACE) combined with camrelizumab and apatinib versus TACE alone in the treatment of unresectable hepatocellular carcinoma eligible for embolization: a multicenter, open-label, randomized, phase 2 study (CAP-ACE). J. Clin. Oncol. 43, 0\u20131 (2025).","journal-title":"J. Clin. Oncol."},{"key":"2718_CR20","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1245\/s10434-020-08601-8","volume":"27","author":"S Li","year":"2020","unstructured":"Li, S. et al. Postoperative adjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of hepatocellular carcinoma patients with microvascular invasion: a preliminary report of a phase III, randomized controlled clinical trial. Ann. Surg. Oncol. 27, 5183\u20135190 (2020).","journal-title":"Ann. Surg. Oncol."},{"key":"2718_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/SLA.0b013e3181961c16","volume":"249","author":"W-P Zhou","year":"2009","unstructured":"Zhou, W.-P. et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann. Surg. 249, 195\u2013202 (2009).","journal-title":"Ann. Surg."},{"key":"2718_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-018-0331-y","volume":"38","author":"W Wei","year":"2018","unstructured":"Wei, W. et al. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun. 38, 1\u201312 (2018).","journal-title":"Cancer Commun."},{"key":"2718_CR23","doi-asserted-by":"publisher","first-page":"e0130021","DOI":"10.1371\/journal.pone.0130021","volume":"10","author":"L Shaohua","year":"2015","unstructured":"Shaohua, L. et al. Surgical strategy for hepatocellular carcinoma patients with portal\/hepatic vein tumor thrombosis. PLOS One 10, e0130021 (2015).","journal-title":"PLOS One"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02718-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02718-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02718-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:02:22Z","timestamp":1778803342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02718-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2718"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02718-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}